- Open Access
Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study
Microbiome volume 4, Article number: 50 (2016)
End-stage renal disease (ESRD) is associated with uremia and increased systemic inflammation. Alteration of the intestinal microbiota may facilitate translocation of endotoxins into the systemic circulation leading to inflammation. We hypothesized that children with ESRD have an altered intestinal microbiota and increased serum levels of bacterially derived uremic toxins.
Four groups of subjects were recruited: peritoneal dialysis (PD), hemodialysis (HD), post-kidney transplant and healthy controls. Stool bacterial composition was assessed by pyrosequencing analysis of 16S rRNA genes. Serum levels of C-reactive protein (CRP), D-lactate, p-cresyl sulfate and indoxyl sulfate were measured.
Compared to controls, the relative abundance of Firmicutes (P = 0.0228) and Actinobacteria (P = 0.0040) was decreased in PD patients. The relative abundance of Bacteroidetes was increased in HD patients (P = 0.0462). Compared to HD patients the relative abundance of Proteobacteria (P = 0.0233) was increased in PD patients. At the family level, Enterobacteriaceae was significantly increased in PD patients (P = 0.0020) compared to controls; whereas, Bifidobacteria showed a significant decrease in PD and transplant patients (P = 0.0020) compared to control. Alpha diversity was decreased in PD patients and kidney transplant using both phylogenetic and non-phylogenetic diversity measures (P = 0.0031 and 0.0003, respectively), while beta diversity showed significant separation (R statistic = 0.2656, P = 0.010) between PD patients and controls. ESRD patients had increased serum levels of p-cresyl sulfate and indoxyl sulfate (P < 0.0001 and P < 0.0001, respectively). The data suggests that no significant correlation exists between the alpha diversity of the intestinal microbiota and CRP, D-lactate, or uremic toxins. Oral iron supplementation results in expansion of the phylum Proteobacteria.
Children with ESRD have altered intestinal microbiota and increased bacterially derived serum uremic toxins.
The intestinal microbiota is the largest symbiotic ecosystem in the human body. The gastrointestinal tract (GI) is colonized by trillions of bacteria. In healthy adults, almost 90 % of the identified fecal microbiota can be classified into two predominant phyla, Bacteroidetes and Firmicutes. The intestinal microbiota is highly variable during the first years of life, reaching an adult-like composition by 3 years and remains relatively stable . Changes in the composition of the intestinal microbiota have been implicated in the pathogenesis of multiple diseases in children and adults [2, 3].
Patients with end stage renal disease (ESRD) have an increase in cardiovascular disease which cannot be explained by traditional risk factors alone. There is evidence that uremia in ESRD disrupts the intestinal barrier structure, specifically the tight junctions, and impairs intestinal motility [4–7]. These changes may facilitate the translocation of endotoxins and bacterial metabolites into the systemic circulation leading to systemic micro-inflammation [8, 9] and increased cardiovascular disease [10–13]. Blood markers such as D-lactate and endotoxin lipopolysaccharide (LPS), which are metabolic products or components of intestinal bacteria, have been used as indicators of intestinal permeability . Evaluation of intestinal wall integrity is a challenge in patients with reduced renal residual function, because it depends on renal excretion of the orally ingested molecules.
Several factors may influence the intestinal microbiota of ESRD patients. The dietary restriction of potassium may inadvertently cause a reduction in the insoluble fiber intake of these patients . This may ultimately lead to a reduction of normal gut flora which ferment fiber to produce short chain fatty acids (SCFA) which act as a key energy source for colorectal tissues and symbiotic microbes . Further, studies in adults demonstrate that uremia results in a shift in the intestinal microbiota, favoring bacteria capable of surviving in the new biochemical environment . The metabolites produced by this altered colonic flora result in the accumulation of uremic toxins such as indoxyl sulfate and p-cresyl sulfate . Eighteen bacterial families with 4-hydroxyphenylacetate decarboxylase (4-Hpd) and tryptophanase are responsible for the formation of p-cresyl sulfate and indoxyl sulfate, respectively [15, 19]. In addition, recent studies have demonstrated that uremia may also increase ammonia production leading to increased luminal pH and resulting in mucosal damage and irritation . These uremic toxins, which are normally excreted by the kidney via tubular secretion, are poorly cleared by dialysis [20–22]. Several investigators have reported an association between elevated levels of p-cresyl sulfate and indoxyl sulfate with an increased risk of cardiovascular disease and other adverse effects in adults with ESRD [23, 24].
The impact of uremia on the intestinal microbiota of pediatric patients with ESRD is unknown. It is also unclear if renal transplantation has an effect on the composition of the intestinal microbiota, uremic toxin production, or systemic inflammation. Hence, our primary aim was to study the intestinal microbiota of pediatric patients with ESRD and after kidney transplantation. Our secondary aim was to evaluate the correlation between altered intestinal microbiota, D-lactate, C-reactive protein (CRP), and the presence of bacterially derived uremic toxins such as p-cresyl sulfate and indoxyl sulfate.
This is a cross sectional study comparing four groups of pediatric patients (2 to 18 years of age). Thirty-nine patients were enrolled: eight patients on hemodialysis (HD), eight patients on peritoneal dialysis (PD), ten patients with a kidney transplant and 13 age-matched healthy controls. Participants were recruited from participating centers of the Midwest Pediatric Nephrology Consortium (Children’s Hospital of New Orleans, Women and Children’s Hospital of Buffalo, and Children’s Healthcare of Atlanta) from June 2014 to March 2015. Patient demographic and clinical characteristics are shown in Table 1.
We excluded patients with history of diabetes, pancreatitis, cirrhosis, inflammatory bowel disease, diarrhea, severe constipation, or use of antibiotics within 1 month. Additional exclusion criteria included kidney transplant recipients with an estimated glomerular filtration rate (eGFR) of less than 60 ml/min/1.73 m2, acute rejection or transplant within the last 6 months. Written informed consent was obtained from a legal guardian or the patient if 18 years old, and assent was obtained in patients older than 7 years. The study was approved by the Louisiana State University Health Sciences Center Institutional Review Board (IRB # 8554).
Stool sample collection
One stool sample (1–2 g) was collected from each subject. We provided instructions describing how to collect stool specimens, place them in nucleic acid preservative, and deliver them to our Research Center within 24 to 48 h after collection. Stool specimens were collected in Assay Assure (Sierra Molecular, Incline Village, NV), which does not require refrigeration. DNA was isolated from the stool samples within 48 h of receipt and stored at −20 °C.
16S rRNA sequencing
Stool DNA was isolated using a QIAamp Fast DNA Stool Mini kit (Qiagen, Germantown, Maryland) modified to include a sonication step. Sequencing and bioinformatics were performed by the Louisiana State University Microbial Genomics Resource Center. The 16S ribosomal DNA hypervariable regions V3 and V4 were PCR-amplified using primers V3F CCTACGGGAGGCAGCAG and V4R GACTACHVGGGTWTCTAAT with Illumina adaptors and molecular barcodes as described in Kozich et al.  to produce 430 base pair (bp) amplicons. Samples were sequenced on an Illumina MiSeq (Illumina, San Diego, CA) using a V3 sequencing kit (300 bp paired end reads).
The forward and reverse-read files were processed through the UPARSE pipeline (drive5, Tiburon, California) . Forward and reverse reads were merged with a merge truncation quality of 2 as recommended by Edgar for Illumina data. Merged amplicons were filtered using a filter truncation quality of ten and resulting amplicons were truncated to a length of 400 bp. Singleton reads (reads that appeared only once across all samples) were removed from the resulting filtered reads and remaining reads were clustered into operational taxonomic units (OTUs) at 97 % similarity. Chimeric OTUs were removed as identified by UCHIME drive5 run against a gold standard reference database (ChimeraSlayer reference database) of nonchimeric sequences.
Finally, the original filtered reads (before dereplication) were mapped to the OTUs using USEARCH drive5 at 97 % identity. QIIME 1.8 (open source, www.qiime.org) was used to pick and align a representative set. The Ribosomal Database Project classifier was used to assign a taxonomic classification to each read in the representative set and a phylogenetic tree was constructed from the representative sequences. Among samples, the minimum read count after filtering was 7371 reads and the median read count after filtering was 13,226 reads. The OTUs were assigned to the lowest possible taxonomic level. Bacterial alpha diversity among groups was calculated using phylogenetic whole tree and Chao 1 within QIIME. The bacterial beta diversity was assessed using the principal coordinates analysis (PCoA) of weighted UniFrac distances within QIIME.
Blood sample collection
Blood specimen was drawn as part of routine laboratory sampling. For HD patients, blood was taken immediately prior to the midweek dialysis session. Using a 5-ml serum separator tube (SST) with polymer gel and clot activator, 5 ml of venous blood was collected. Following standard separation procedure, serum was isolated and stored at −80 °C. Renal function was assessed by measuring blood urea nitrogen (BUN) and creatinine then calculating the estimated glomerular filtration rate (eGFR) using the modified Schwartz formula  (Table 1).
Bacterially derived uremic toxins
Serum p-cresyl sulfate and indoxyl sulfate were measured by high performance liquid chromatography (HPLC) as described by de Loor et al. . Briefly, two aliquots of 200 μL of serum were added 20 μL of 0.50 mM 1-naphthalenesulfonic acid (internal standard) and vortex-mixed with 250 μL of 0.24 M sodium octanoate (binding competitor). After incubation at room temperature for 5 min, 2 mL of cold acetone was added to precipitate proteins. Following vortex-mixing and centrifuging at 4°C, 1860×g for 20 min, the supernatant was transferred to 12 × 100 mm, GL 14 glass test tubes and 2 mL of dichloromethane was then added. After vortex-mixing and centrifuging at 4°C, 1860×g for 10 min, 200 μL of the upper layer was transferred to glass auto-sampler vials, followed by addition of 20 μL 1 M HCl. 15 μL of this final solution was used for HPLC analysis.
A Shimadzu (Columbia, MD) Prominence LC-20AT HPLC system with UV/Fluorescence detector and auto sampler was used for determination of p-cresyl sulfate and indoxyl sulfate. The analytes were resolved by using a reverse phase Sunfire C18 column (150 × 3.0 mm; 3.5 μm particle size; Waters) with a Sunfire C18 guard column (20 × 3.0 mm; 3.5 μm particle size; Waters) at a flow rate of 0.5 ml/min. Mobile phase A was 0.2 % trifluoroacetic acid in Milli-Q water and mobile phase B was 0.2 % trifluoroacetic acid in acetonitrile. The analytical method consisted of a run with gradient elution starting at 8 % phase B for 5 min, followed by a linear increase to 18 % in 15 min, a linear change to 100 % in 5 min, a hold for 3 min and a final linear change back to 8 % phase B in 2 min, a return to the initial condition for 10 min before next injection. Indoxyl sulfate eluted at 13.8 min, p-cresyl sulfate at 20.4 min and internal standard at 23.7 min. Column temperature was 25 °C, and autosampler tray temperature was 6 °C. We quantified the analytes by using the analyte to standard peak area ratios on a Shimadzu RF-20A xs fluorescence detector. Detector settings were λex 260 nm/λem 288 nm for p-cresyl sulfate and λex 280 nm/λem 390 nm for indoxyl sulfate and internal standard.
Calibrators containing indoxyl sulfate and p-cresyl sulfate at a final concentration between 1.5 and 400.0 μM were prepared in phosphate buffered saline. Two calibration curves were constructed with a linear response ranging from 1.5 to 50.0 μM (low) and 1.5 to 400.0 μM (high). Regression equations were reported as mean (standard deviation (SD)) from three independent curves for indoxyl sulfate were as follows:
y = 0.06 × (0.00072) + 0.3 (0.11) (high curve)
y = 0.07(0.0018) × ‐ 0.01 (0.0042) (low curve)
The regression equations for p-cresyl sulfate were as follows:
y = 0.0083(0.00057) × + 0.02(0.0088) (high curve)
y = 0.0092(0.00036) × + 0.003(0.00086) (low curve)
Overall coefficient of determination (R2) was 0.999
Inflammatory marker and D-lactate measurement
Serum CRP was determined using the human C-Reactive Protein ELISA kit (Sigma-Aldrich, St. Louis, MO) according to manufacturer’s instruction. Serum D-lactate level was determined using the D-lactate colorimetric assay kit (Sigma-Aldrich, St. Louis, MO) according to the manufacturer’s instruction.
Alpha diversity was measured using phylogenetic diversity whole tree and Chao1 within QIIME, using the average of ten iterations in which 6600 sequences were randomly sampled from each specimen. Diversity was compared between PD, HD, post-transplant, and control groups. Statistical differences in bacterial community composition between groups of specimens were assessed using analysis of similarity (ANOSIM) and principal coordinates analysis (PCoA) of weighted UniFrac distances within QIIME . Comparison of multiple groups was performed by the nonparametric Kruskal-Wallis test followed by Dunn’s multiple comparisons test within GraphPad PRISM 6 (Graph Pad Software Inc., San Diego, CA). Correlation analysis was assessed by Spearman nonparametric correlation within PRISM. Box and whisker plots illustrate median (line within the box) and minimum and maximum values (whiskers).
Relative abundance of bacterial taxa
There were notable differences in the relative abundances of intestinal bacteria at the phylum level between patient groups (Fig. 1). The relative abundance of bacteria within the phylum Firmicutes was significantly lower in PD patients (P = 0.0228) compared to healthy controls (Fig. 2a). Whereas the relative abundance of the phylum Bacteroidetes was significantly increased in HD patients (P = 0.0462) compared to healthy controls (Fig. 2b). There were also significant differences in the relative abundances of phyla across dialysis modalities. The phylum Proteobacteria was significantly increased in patients on PD (P = 0.0233) compared to patients on HD (Fig. 2c). Actinobacteria was significantly decreased in PD patients (Fig. 2d) compared to controls (P = 0.0040).
Alpha diversity was significantly decreased in patients on PD and in patients with kidney transplants, when compared to patients on HD and controls, using both phylogenetic (Fig. 3a) and non-phylogenetic (Fig. 3b) diversity measures (P = 0.0031 and 0.0003, respectively).
Bacterial community composition
PCoA analysis of weighted UniFrac distances showed significant separation between microbial communities (Fig. 4) of patients with ESRD on PD compared to healthy control group, (R statistic = 0.2656, P = 0.010, ANOSIM).
Indole and P-cresol producing taxa
Enterobacteriaceae was significantly increased in patients with ESRD who were on PD (Fig. 5a) compared to controls (P = 0.0020). We found no significant difference in Clostridiaceae across any patient groups (Fig. 5b). Bifidobacteriaceae was significantly decreased (P = 0.0020) in PD and with kidney transplant patients when compared to controls (Fig. 5c). There was no significant difference observed in the Lactobacillaceae family between any of the patient groups (Fig. 5d).
Serum p-cresyl sulfate and indoxyl sulfate levels
Patients with ESRD, either on HD or PD, had significantly increased levels of the uremic toxins p-cresyl sulfate (P < 0.0001) and indoxyl sulfate (P < 0.0001) compared to control and transplant patients (Fig. 6a, b, respectively). There was no significant difference between HD and PD patients.
Serum CRP and D-lactate
Correlation of species richness and serum biomarkers
There was no significant correlation between alpha diversity measures (PD whole tree) and serum CRP, D-lactate, or uremic toxins (Fig. 8).
To our knowledge, this study is the first to assess the composition of the intestinal microbiota of pediatric patients with ESRD or kidney transplants. Recent studies have revealed the fundamental role of the intestinal microbiota in the maintenance of normal human physiology and homeostasis. This complex ecosystem within the gut is highly susceptible to disturbances that can alter the composition of the intestinal microbiota. We demonstrate that children and adolescents with ESRD and kidney transplant exhibit an altered intestinal microbiota. PD patients, as well as those with a kidney transplant, exhibited significantly decreased bacterial diversity (alpha diversity) compared to control. In addition, the composition of bacterial communities (beta diversity) within our PD patients was significantly different when compared to the healthy control group. Serum levels of bacterially derived uremic toxins, p-cresyl and indoxyl sulfate, were significantly increased in ESRD patients.
The GI tract hosts a broad range of bacterial species. It is estimated that between 500 and 1000 species are resident at any given time, but four divisions predominate: Firmicutes, Bacteroidetes, Proteobacteria, and Actinobacteria. Firmicutes constitute ~64 % of the microbiota, whereas Bacteroidetes account for ~23 % of the normal microbiota . In chronic conditions such as type 2 diabetes mellitus and inflammatory bowel disease, patients develop dysbiosis, defined as an abnormal ratio of beneficiary and aggressive bacterial species . We found that patients with ESRD on PD had a decreased relative abundance of the phylum Firmicutes (Fig. 2a), while HD patients exhibited an increase to the phylum Bacteroidetes (Fig. 2b) when compared to healthy control patients. The same pattern of gut dysbiosis was reported in patients with type-2 diabetes .
In addition to uremia, several possible mechanisms may account for the observed changes to the intestinal microbiota. Proteobacteria, also known as the iron oxidizing bacteria, are typically present in small amounts in the healthy adult intestinal microbiota . However, our results demonstrate that Proteobacteria were increased in patients on PD (Fig. 2c) when compared to HD patients. This may be due to the oral iron supplementation received by PD patients. Although both ESRD groups receive iron supplementation, the route of delivery differs for the two dialysis modalities. Whereas HD patients receive iron supplementation directly into the bloodstream, PD patients ingest iron supplements. The interaction of orally ingested iron with gut microbes able to metabolize this mineral may account for the increased Proteobacteria levels. Further, Enterobacteriaceae, a family belonging to the phylum Proteobacteria, exhibited a significant increase in abundance among PD patients compared to control patients (Fig. 5a). The Enterobacteriaceae are known to ferment glucose and account for up to 12 % of all peritonitis episodes in patients with ESRD treated with PD . We speculate that the observed increase in Enterobacteriaceae in PD patients may be due to intestinal absorption of glucose from the dialysate. This increase in Enterobacteriaceae may contribute to peritonitis infections observed in PD patients. Future studies are needed to better evaluate these findings.
Patients on PD had a significantly decreased abundance of the phylum Actinobacteria (Fig. 2d). Conversely, Wu et al. demonstrated that increased Actinobacteria was associated with a healthy gut microbiome in children . Bifidobacterium, a family belonging to the phylum Actinobacteria, also exhibited a decreased abundance in PD and kidney transplant patients (Fig. 5c). These organisms might be responsible for a variety of beneficial health effects, including the regulation of intestinal microbial homeostasis and the inhibition of harmful bacteria that colonize or infect the gut mucosa . Bifidobacterium improve the gut mucosal barrier and lower levels of lipopolysaccharide in the intestine . Alterations in the integrity of the intestinal mucosa facilitate the translocation of bacterially derived toxins.
Loss of bacterial diversity has been shown to play a role in the severity of clinical features of infants with necrotizing enterocolitis (NEC)  and adult patients with chronic obstructive lung disease (COPD) . This suggests an association between loss of bacterial diversity and disease severity. There was a significant decrease in the number of species (alpha diversity) in our patients on PD and with a kidney transplant, when compared to patients on HD and controls using both phylogenetic (Fig. 3a) and non-phylogenetic diversity measures (Fig. 3b). In future studies, we will address the question of whether the observed alpha diversity in children with ESRD affects the severity or rate of complications. Results of the beta diversity analysis, illustrated by PCoA plot (Fig. 4), showed a significant difference in UniFrac distances between ESRD on PD and control microbial communities. Our results represent an initial insight into the intestinal microbiome patterns in ESRD, which would need to be confirmed in larger cohorts.
Of note, transplant patients exhibited decreased species diversity and decreased abundance of Bifidobacteria (Fig. 3a, b, and Fig. 5c, respectively). Several studies have reported shifts in gut microbiota, including loss of dominant phyla and decreased species diversity, following organ transplantation [40–42]. These alterations may be the result of antibiotic treatment, immunosuppression therapy or a combination of the two. Further studies will be needed to elucidate the mechanism by which these alterations are occurring.
Serum concentrations of p-cresyl sulfate and indoxyl sulfate have been associated with progression of chronic kidney disease [21, 23], increased cardiovascular disease [10–13] and overall mortality in adult patients with chronic kidney disease. Previous studies found that the high protein binding affinity of both bacterially derived uremic toxins markedly limits their removal by dialysis, even with the use of high-flux membranes . Serum levels of p-cresyl sulfate and indoxyl sulfate seem to correlate with loss of residual renal function . Recent animal studies, demonstrated that p-cresyl sulfate and indoxyl sulfate are excreted by renal tubular secretion via organic anion transporters . Similar to adult studies, we found significantly increased levels of p-cresyl sulfate and indoxyl sulfate in our pediatric patients with ESRD. Kidney transplantation results in normalization of serum indoxyl sulfate and p-cresyl sulfate, despite decreased bacterial diversity. These findings suggest that renal clearance via tubular secretion is of paramount importance for maintaining normal serum levels of both toxins. Accumulation of these uremic toxins is considered one of the possible causes of chronic inflammation in patients with ESRD.
Chronic inflammation is a well-established independent risk factor for cardiovascular disease. Patients with ESRD have a high prevalence of micro-inflammation [46–49]. In recent years, several studies have tried to elucidate the etiology for this inflammatory state. The relative roles of residual renal function, dialysis modality, bacterial translocation, intestinal microbiota and the accumulation of endotoxins such as p-cresyl sulfate and indoxyl sulfate in causing the inflammatory milieu of CKD remains unclear. In our study, we assessed inflammation by measuring serum CRP, but did not observe a statistical difference between our groups of patients. There was a trend toward higher serum CRP levels in the patients with ESRD; however, the lack of statistical significance may have been due to the high variation and small sample sizes. Furthermore, we discovered that several of our control patients were overweight or obese, which is a confounding factor for inflammatory markers. Visser et al. demonstrated that higher BMI was associated with increased CRP levels .
Evidence suggests that uremia may impair the intestinal barrier function of ESRD patients [4–7]. This “leaky gut” may allow the passage of endotoxins and bacterial metabolites into the systemic circulation contributing to systemic microinflammation [8, 9]. For this study, serum D-lactate was used as an indirect marker of intestinal permeability. There were no significant differences observed between the groups. Although a previous study reports elevated plasma D-lactate levels in ESRD patients, this observation was only seen in conjunction with the presence of bacterial DNA in blood samples . Our study of serum D-lactate level does not include simultaneous analysis of bacterial DNA in blood samples. This suggests that D-lactate alone may not independently indicate the level of intestinal permeability in ESRD patients.
The level of species richness, as measured by PD whole tree, did not show a significant correlation with any of the serum biomarkers used in this study. As stated above, several factors may contribute to the lack of correlation and statistically significant differences among these groups of study. Although some studies have demonstrated the correlation between specific intestinal microbes and biomarkers, to our knowledge this is the first study to attempt to link the overall intestinal species diversity with serum biomarkers in a pediatric population. Further studies of larger cohort populations will be needed to validate the results of this study.
Recent studies suggest that uremic by-products induce toxicity by increasing the production of reactive oxygen species (ROS) through NADPH oxidase (membrane-bound enzyme complex that generate superoxide). ROS production generates the mitogen-activated protein kinase (MAPK)/NF-kB (nuclear factor kB) pathway which leads to the production of pro-inflammatory cytokines, chemokines and adhesion molecules [51, 52]. Measurement of ROS in pediatric ESRD patients is a potential avenue of investigation.
There are limitations in our study. Our sample size was small, and this limited our statistical power. We were unable to control for potential confounding variables such as dietary restrictions or BMI.
We have demonstrated that pediatric patients with ESRD and kidney transplant have an altered intestinal microbiota. The intestinal microbiota of ESRD patients differs with dialysis modality.
Patients with ESRD have elevated levels of p-cresyl sulfate and indoxyl sulfate.
Renal transplantation results in the normalization of bacterially derived uremic toxins p-cresyl sulfate and indoxyl sulfate; however, renal transplantation does not correct the decreased bacterial diversity.
analysis of similarity
one-way analysis of variance
blood urea nitrogen
estimated glomerular filtration rate
end-stage renal disease
high-performance liquid chromatography
mitogen-activated protein kinase
nuclear factor kB
operational taxonomic units
principal coordinates analysis
reactive oxygen species
serum separator tube
Rodríguez JM, Murphy K, Stanton C, Ross RP, Kober O, Juge N, et al. The composition of the gut microbiota throughout life, with an emphasis on early life. Microb Ecol Health Dis. 2015;26:26050.
Arrieta MC, Stiemsma LT, Amenyogbe N, Brown EM, Finlay B. The intestinal microbiome in early life: health and disease. Front Immunol. 2014;5:427.
Mitsuoka T. Intestinal flora and human health. Asia Pac J Clin Nutr. 1996;5:2–9.
Vaziri ND. CKD impairs barrier function and alters microbial flora of the intestine: a major link to inflammation and uremic toxicity. Curr Opin Nephrol Hypertens. 2012;21:587–92.
Vaziri ND, Yuan J, Nazertehrani S, Ni Z, Liu S. Chronic kidney disease causes disruption of gastric and small intestinal epithelial tight junction. Am J Nephrol. 2013;38:99–103.
Vaziri ND, Yuan J, Norris K. Role of urea in intestinal barrier dysfunction and disruption of epithelial tight junction in CKD. Am J Neprol. 2013;37:1–6.
Nagib EM, El-Sayed MH, Ahmed MA, Youssef MH. Intestinal motility in acute uremia and effects of erythropoietin. Saudi Med J. 2012;33:500–7.
Wang F, Zhang P, Jiang H, Cheng S. Gut bacterial translocation contributes to microinflammation in experimental uremia. Dig Dis Sci. 2012;57:2856–62.
Wang F, Jiang H, Shi K, Ren Y, Zhang P, Cheng S. Gut bacterial translocation is associated with microinflammation in end-stage renal disease patients. Nephrology (Carlton). 2012;17:733–8.
Chiu CA, Lu LF, Yu TH, Hung WC, Chung FM, Tsai IT, et al. Increased levels of total P-cresyl sulphate and indoxyl sulphate are associated with coronary artery disease in patients with diabetic nephropathy. Rev Diabet Stud. 2010;7:275–84.
Watanabe H, Miyamoto Y, Enoki Y, Ishima Y, Kadowaki D, Kotani S, et al. p-Cresyl sulfate, a uremic toxin, causes vascular endothelial and smooth muscle cell damages by inducing oxidative stress. Pharmacol Res Perspect. 2015. doi:10.1002/prp2.92.
Poesen R, Viaene L, Verbeke K, Augustijns P, Bammens B, Claes K, et al. Cardiovascular disease relates to intestinal uptake of p-cresol in patients with chronic kidney disease. BMC Nephrol. 2014. doi:10.1186/1471-2369-15-87.
Shunsuke I, Masayuki Y. Protein-bound uremic toxins: new culprits of cardiovascular events in chronic kidney disease patients. Toxins (Basel). 2014;6:665–78.
Derikx JP, Luyer MD, Heineman E, Buurman WA. Non-invasive marker of gut wall integrity in health and disease. World J Gastroenterol. 2010;16:5272–9.
Wong J, Piceno YM, Desantis TZ, Pahl M, Andersen GL, Vaziri ND. Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am J Nephrol. 2014;39(3):230–7.
Conlon MA, Bird AR. The impact of diet and lifestyle on gut microbiota and human health. Nutrients. 2014;7(1):17–44.
Vaziri ND, Wong J, Pahl M, Piceno YM, Yuan J, DeSantis TZ, et al. Chronic kidney disease alters intestinal microbial flora. Kidney Int. 2013;83:308–15.
Aronov PA, Luo FJ, Plummer NS, Quan Z, Holmes S, Hostetter TH, et al. Colonic contribution to uremic solutes. J Am Soc Nephrol. 2011;22:1769–76.
Rossi M, Campbell KL, Johnson DW. Indoxyl sulphate and p-cresyl sulphate: therapeutically modifiable nephrovascular toxins. OA Nephrology. 2013;1(2):13.
Lin CJ, Wu CJ, Pan CF, Chen YC, Sun FJ, Chen HH. Serum protein-bound uraemic toxins and clinical outcomes in haemodialysis patients. Nephrol Dial Transplant. 2010;25:3693–700.
Watanabe H, Miyamoto Y, Honda D, Tanaka H, Wu Q, Endo M, et al. P-cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase. Kidney Int. 2013;83:582–92.
Poesen R, Viaene L, Verbeke K, Claes K, Bammens B, Sprangers B, et al. Renal clearance and intestinal generation of p-cresyl sulfate and indoxyl sulfate in CKD. Clin J Am Soc Nephrol. 2013;8:1508–14.
Wu IW, Hsu KH, Lee CC, Sun CY, Hsu HJ, Tsai CJ, et al. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant. 2011;26:938–47.
Vanholder R, Bammens B, de Loor H, Glorieux G, Meijers B, Schepers E, et al. Warning: the unfortunate end of p-cresol as a uraemic toxin. Nephrol Dial Transplant. 2011;26:1464–7.
Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD. Development of a dual index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. Appl Environ Microbiol. 2013;79:5112–20.
Edgar RC. UPARSE: highly accurate OUT sequences from microbial amplicon reads. Nat Methods. 2013;10:996–8.
Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20:629–37.
de Loor H, Meijers BK, Meyer TW, Bammens B, Verbeke K, Dehaen W, et al. Sodium octanoate to reverse indoxyl sulfate and p-cresyl sulfate albumin binding in uremic and normal serum during sample preparation followed by fluorescence liquid chromatography. J Chromatogr A. 2009;1216:4684–8.
Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010;7:335–6.
Sartor RB, Mazmanian SK. Intestinal microbes in inflammatory bowel disease. Am J Gastroenterol. 2012;(Suppl 1):15–21. doi:10.1038/ajgsup.2012.4.
Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux JJ, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008;105:16731–6.
Larsen N, Vogensen FK, van den Berg FW, Nielsen DS, Andreasen AS, Pedersen BK, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One. 2010. doi:10.1371/journal.pone.0009085.
Heidrich S, Schlöman M, Johnson DB. The iron-oxidizing proteobacteria. Microbiology. 2011;157:1551–64.
Szeto CC, Chow VC, Chow KM, Lai RW, Chung KY, Leung CB, et al. Enterobacteriaceae peritonitis complicating peritoneal dialysis: a review of 210 consecutive cases. Kidney Int. 2006;69:1245–52.
Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011;334(6052):105–8.
Cummings JH, Macfarlane GT. Gastrointestinal effects of prebiotics. Br J Nutr Suppl. 2002;2:S145–51.
Pinzone MR, Celesia BM, Di Rosa M, Cacopardo B, Nunnari G. Microbial translocation in chronic liver diseases. Int J Microbiol. 2012. doi:10.1155/2012/694629.
McMurtry VE, Gupta RW, Tran L, Blanchard 4th EE, Penn D, Taylor CM, et al. Bacterial diversity and Clostridia abundance decrease with increasing severity of necrotizing enterocolitis. Microbiome. 2015. doi:10.1186/s40168-015-0075-8.
Garcia-Nuñez M, Millares L, Pomares X, Ferrari R, Pérez-Brocal V, Gallego M, et al. Severity-related changes of bronchial microbiome in chronic obstructive pulmonary disease. J Clin Microbiol. 2014;52:4217–23.
Wu ZW, Ling ZX, Lu HF, Zuo J, Sheng JF, Zheng SS, et al. Changes of gut bacteria and immune parameters in liver transplant recipients. Hepatobiliary Pancreat Dis Int. 2012;11(1):40–50.
Lu H, He J, Wu Z, Xu W, Zhang H, Ye P, et al. Assessment of microbiome variation during the perioperative period in liver transplant patients: a retrospective analysis. Microb Ecol. 2013;65(3):781–91.
Lee JR, Muthukumar T, Dadhania D, Toussaint NC, Ling L, Pamer E, et al. Gut microbial community structure and complications after kidney transplantation: a pilot study. Transplantation. 2014;98(7):697–705.
Martinez AW, Recht NS, Hostetter TH, Meyer TW. Removal of p-cresol sulfate by hemodialysis. J Am Soc Nephrol. 2005;16:3430–6.
Viaene L, Meijers BK, Bammens B, Vanrenterghem Y, Evenepoel P. Serum concentrations of p-cresyl sulfate and indoxyl sulfate, but not inflammatory markers, increase in incident peritoneal dialysis patient in parallel with loss of residual renal function. Perit Dial Int. 2014;34:71–8.
Watanabe H, Sakaguchi Y, Sugimoto R, Kaneko K, Iwata H, Kotani S, et al. Human organic anion transporters function as a high-capacity transporter for p-cresyl sulfate, a uremic toxin. Clin Exp Nephrol. 2014;18:814–20.
Kotanko P, Carter M, Levin NW. Intestinal bacterial microflora—a potential source of chronic inflammation in patients with chronic kidney disease. Nephrol Dial Transplant. 2006;21:2057–60.
Shi K, Wang F, Jiang H, Liu H, Wei M, Wang Z, et al. Gut bacterial translocation may aggravate microinflammation in hemodialysis patients. Dig Dis Sci. 2014;59:2109–17.
Hsu HJ, Yen CH, Wu IW, Hsu KH, Chen CK, Sun CY, et al. The association of uremic toxins and inflammation in hemodialysis patients. PLoS One. 2014. doi:10.1371/journal.pone.0102691.
Lau WL, Kalantar-Zadeh K, Vaziri ND. The gut as a source of inflammation in chronic kidney disease. Nephron. 2015;130:92–8.
Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282(22):2131–5.
Niwa T, Shimizu H. Indoxyl sulfate induces nephrovascular senescence. J Ren Nutr. 2012;22:102–6.
Soulage C, Koppe L, Fouque D. Protein-bound uremic toxins new targets to prevent insulin resistance and dysmetabolism in patients with chronic kidney disease. J Ren Nutr. 2013;23:464–6.
This study was supported in part by National Institutes of Health Grant 2G12MD007595.
Availability of data and materials
The sequence data and mapping file for all the samples included in this study have been deposited in Figshare (http://dx.doi.org/10.6084/m9.figshare.3394087).
JCS coordinated, participated in all analyses, performed experiments, and drafted the manuscript. VMV, TS, MF, QZ, GW, MK, LG, and DA were involved in drafting the manuscript. TS, QZ, GW, and MF performed experiments and analyzed data. DA, MK, and LG provided patient samples. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Louisiana State University Health Sciences Center Institutional Review Board (IRB # 8554). All subjects or parents provided written consent prior to the execution of the study. They also gave consent for publication.
About this article
Cite this article
Crespo-Salgado, J., Vehaskari, V.M., Stewart, T. et al. Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study. Microbiome 4, 50 (2016). https://doi.org/10.1186/s40168-016-0195-9
- End-stage renal disease
- Intestinal microbiota
- Uremic toxins